TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34928960

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma transfusion
Number of subjects: 105717
Study: 35238725

Group type: COMPARATOR
Intervention: Intravenous (IV) belimumab 10 mg/kg dose Q2W for three doses, then 10 mg/kg Q4W thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous (SC) belimumab 400 mg dose QW for four doses, then 200 mg QW thereafter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belimumab (both IV and SC)
Number of subjects: 0
Study: 33406220

Group type: EXPERIMENTAL
Intervention: Weekly e‐mails with audiovisual links
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional communication (verbal and written instructions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Weekly text messages
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Household income (high)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parents' education (high)
Number of subjects: 120
Study: 34320040

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification Program (IMP) - 5 sessions guiding benign interpretations
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification Program (IMP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Number of subjects: 51
Study: 33291727

Group type: EXPERIMENTAL
Intervention: Video condition (n = 38)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Static-sequential-permanent pictures condition (n = 36)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Static-simultaneous-permanent pictures condition (n = 30)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Static-sequential-transient pictures condition (n = 29)
Number of subjects: 133
Study: 36337766

Group type: COMPARATOR
Intervention: CUPG
Number of subjects: 139

Group type: COMPARATOR
Intervention: ACUG
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CTRG
Number of subjects: 139
Study: 34280843

Group type: EXPERIMENTAL
Intervention: Interferon beta treatment
Number of subjects: 50
Study: 35613415

Group type: EXPERIMENTAL
Intervention: Aerobic exercise + mindfulness meditation (AE + MM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 32
Study: 33627334

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32242144

Group type: EXPERIMENTAL
Intervention: 25 hydroxyvitamin D (25OHD) concentration
Number of subjects: 417580

Group type: EXPERIMENTAL
Intervention: Mendelian randomization models
Number of subjects: 417580

Group type: EXPERIMENTAL
Intervention: Causal effects of phenotypes on 25OHD concentration
Number of subjects: 417580
Study: 34274955

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Cardiovascular events (CVE)
Number of subjects: 453
Study: 32143730

Group type: EXPERIMENTAL
Intervention: Capecitabine metronomic chemotherapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Capecitabine conventional chemotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Overall survival, safety, and quality of life
Number of subjects: 158
Study: 35839452

Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 296
Study: 34254537

Group type: EXPERIMENTAL
Intervention: Nutrition intervention for dietary and lifestyle modification for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 36155502

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Balance and tone training (control)
Number of subjects: 32
Study: 33493028

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial intelligence algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline 18F-sodium florid activity
Number of subjects: 0
Study: 32703201

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 90
Study: 36354040

Group type: EXPERIMENTAL
Intervention: LY3437943 3 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LY3437943 3/6 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LY3437943 3/6/9/12 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LY3437943
Number of subjects: 72
Study: 33961863

Group type: EXPERIMENTAL
Intervention: Active stimulation to the dorsomedial prefrontal cortex (dmPFC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Active stimulation to the right temporoparietal junction (rTPJ)
Number of subjects: 69
Study: 32739150

Group type: EXPERIMENTAL
Intervention: 3DCT reconstructions with subtraction of unfractured bones
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3DCT reconstructions without subtraction of unfractured bones
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for non-trauma surgeons
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for fracture characteristics
Number of subjects: 20
Study: 35579350

Group type: EXPERIMENTAL
Intervention: Custodiol-N
Number of subjects: 101

Group type: COMPARATOR
Intervention: Custodiol
Number of subjects: 101
Study: 33605791

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 6914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6914
Study: 34414678

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32730985

Group type: EXPERIMENTAL
Intervention: MSC+allograft
Number of subjects: 73

Group type: COMPARATOR
Intervention: AICBG
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 35860804

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study: 34490493

Group type: EXPERIMENTAL
Intervention: Dynamic [18F]FET PET radiomics (TTP model)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Early static [18F]FET PET radiomics (TBR5-15 model)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Standard static [18F]FET PET radiomics (TBR20-40 model)
Number of subjects: 159
Study: 35143622

Group type: EXPERIMENTAL
Intervention: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by observation in responding patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by bortezomib maintenance in responding patients
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ctDNA monitoring after induction
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ctDNA dynamics assessment during the bortezomib window
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ctDNA negativity after induction
Number of subjects: 53
Study: 35017939

Group type: EXPERIMENTAL
Intervention: Experimental group (extraction of contralateral premolars on the 28th day after bonding)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (extraction of permanent first premolars on day 1 of bonding)
Number of subjects: 40
Study: 33788452

Group type: EXPERIMENTAL
Intervention: Governor Vessel moxibustion therapy, applied once a week for 8 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin calcium tablets (10 mg) once daily for 8 weeks (Control).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Governor Vessel moxibustion therapy (I) vs Atorvastatin (C) for CAS clinical effect.
Number of subjects: 100
Study: 33010491

Group type: EXPERIMENTAL
Intervention: Surgical group (19 common invasive procedures)
Number of subjects: 183430

Group type: COMPARATOR
Intervention: Control group (10% random sample of non-surgical patients)
Number of subjects: 183430
Study: 33340853

Group type: EXPERIMENTAL
Intervention: CAPOX with continuous oxaliplatin (8 cycles of CAPOX)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CAPOX with intermittent oxaliplatin (2 cycles of CAPOX, 4 cycles of capecitabine, and 2 cycles of CAPOX)
Number of subjects: 200
Study: 32543150

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NovoRapid®
Number of subjects: 24
Study: 35989940

Group type: EXPERIMENTAL
Intervention: USL (digital therapeutic app)
Number of subjects: 98

Group type: COMPARATOR
Intervention: WN (White Noise Lite app)
Number of subjects: 98
Study: 33883300

Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability, prescribed at 3 sessions per week for 4 or 6 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability with coaching and individualized progressions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability.
Number of subjects: 0
Study: 34130213

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 35734953

Group type: EXPERIMENTAL
Intervention: Yellow yeast rice (YYR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 34374529

Group type: EXPERIMENTAL
Intervention: ssDNA triplex-forming oligos (TFOs) at pH 5
Number of subjects: 67000000

Group type: EXPERIMENTAL
Intervention: ssDNA triplex-forming oligos (TFOs) at pH 7
Number of subjects: 67000000

Group type: EXPERIMENTAL
Intervention: Triplex-forming motifs (TFMs) identified from the oligo library
Number of subjects: 67000000

Group type: EXPERIMENTAL
Intervention: Single-variant verification experiments with TFOs containing TFMs
Number of subjects: 67000000
Study: 36310890

Group type: EXPERIMENTAL
Intervention: Group-directed video instruction module
Number of subjects: 99

Group type: COMPARATOR
Intervention: Instructor-led traditional classroom instruction module
Number of subjects: 99
Study: 33434629

Group type: EXPERIMENTAL
Intervention: Ketogenic very low calorie diet (VLCD), video consultations, educational resources
Number of subjects: 24
Study: 36164012

Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB) 200 mg QD
Number of subjects: 130

Group type: COMPARATOR
Intervention: Danazol (DAN) 600 mg QD
Number of subjects: 130
Study: 34033117

Group type: EXPERIMENTAL
Intervention: High-dose right unilateral ECT (6 × seizure threshold)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bitemporal ECT (1.5 × seizure threshold)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Psychotic features at pre-ECT baseline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Greater number of previous depressive episodes
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bipolar II diagnosis
Number of subjects: 61
Study: 33574056

Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 1
Number of subjects: 261647

Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 2
Number of subjects: 261647

Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 3
Number of subjects: 261647

Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model
Number of subjects: 261647
Study: 36480346

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program combined with music therapy
Number of subjects: 120
Study: 32931612

Group type: EXPERIMENTAL
Intervention: 400 units of vitamin E/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 1,000 mg of vitamin C/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 400 units of vitamin E and 1,000 mg of vitamin C/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 32640132

Group type: EXPERIMENTAL
Intervention: Nemolizumab (60 mg subcutaneously every 4 weeks)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 4 weeks)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Nemolizumab
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 36517320

Group type: EXPERIMENTAL
Intervention: Streamlined pediatric anxiety program (six lessons, 20-30 minutes each)
Number of subjects: 0
Study: 32800029

Group type: EXPERIMENTAL
Intervention: Daily inhalation of budesonide 200 μg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intermittent inhalation of budesonide 200 μg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study: 35133884

Group type: EXPERIMENTAL
Intervention: Blonanserin 16 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Blonanserin 8 mg/day
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 33973914

Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging with EDTA
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional packaging with EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging without EDTA
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional packaging without EDTA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Finger contamination
Number of subjects: 38
Study: 36095195

Group type: EXPERIMENTAL
Intervention: Daytime and nighttime eating during simulated night work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daytime-only eating during simulated night work
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated day work (baseline)
Number of subjects: 0
Study: 34067524

Group type: EXPERIMENTAL
Intervention: Magnesium supplement (450 mg for men, 300 mg for women)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (water without magnesium supplement)
Number of subjects: 19
Study: 34579601

Group type: EXPERIMENTAL
Intervention: Recent HIV diagnosis
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: HIV-related stigma
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Social support score
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Population-attributable risk percent
Number of subjects: 824
Study: 33306418

Group type: EXPERIMENTAL
Intervention: Denosumab biosimilar (60 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Denosumab biosimilar
Number of subjects: 52
Study: 32215798

Group type: EXPERIMENTAL
Intervention: ≤ 25% pink dye effluent
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ≤ 25% violet dye effluent
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ≤ 10% black dye effluent
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher concentrations of heavy metals (Pb, Cr, Fe, Mn)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Survey data
Number of subjects: 28
Study: 35615783

Group type: EXPERIMENTAL
Intervention: Probiotic peanut oral immunotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 34431258

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA)
Number of subjects: 112
Study: 36476455

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AZD1222) vaccine
Number of subjects: 174
Study: 34134027

Group type: EXPERIMENTAL
Intervention: Integrated Mothers and Babies Course and Early Childhood Development (iMBC/ECD)
Number of subjects: 417

Group type: COMPARATOR
Intervention: ECD only content (Control)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: iMBC/ECD (for sub-group with high program attendance)
Number of subjects: 417
Study: 32386476

Group type: EXPERIMENTAL
Intervention: parecoxib plus propacetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: propacetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 33385521

Group type: EXPERIMENTAL
Intervention: Palbociclib plus exemestane
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 601

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Palbociclib plus ET
Number of subjects: 601
Study: 32410715

Group type: EXPERIMENTAL
Intervention: Cognitive video-game training (CI) + endurance, strength, and music-movement coordination (EI)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cognitive video-game training (CI) + stretching, toning, and relaxation (EC)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Video games not specifically designed to train cognition (CC) + endurance, strength, and music-movement coordination (EI)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Video games not specifically designed to train cognition (CC) + stretching, toning, and relaxation (EC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cognitive training (CI or CC) + physical control activity (EC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Physical training (EI or EC) + cognitive control activity (CC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Combination of both control activities (CC + EC)
Number of subjects: 144
Study: 35200145

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (wearable device + mobile app)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard intervention (wearable device only)
Number of subjects: 221
Study: 33308122

Group type: EXPERIMENTAL
Intervention: Qingpeng ointment with routine medical treatment and rehabilitative care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment without Qingpeng ointment
Number of subjects: 120
Study: 35548968

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid and ipidacrine hydrochloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 32
Study: 32092208

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 34875207

Group type: EXPERIMENTAL
Intervention: Group A (spherical aberration -0.27 μm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B (spherical aberration -0.20 μm)
Number of subjects: 60
Study: 34407826

Group type: EXPERIMENTAL
Intervention: Talking therapy for depression
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Engagement of the study team with the clinical recruitment site
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Frequent presence of a researcher in clinics
Number of subjects: 14
Study: 32041669

Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection
Number of subjects: 142

Group type: COMPARATOR
Intervention: Intravitreal dexamethasone implant (700 μg)
Number of subjects: 142
Study: 616461890

Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate diet (65% energy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy), higher fat (35% energy), lower carbohydrate (45% energy)
Number of subjects: 242
Study: 36225132

Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension administered orally
Number of subjects: 36

Group type: COMPARATOR
Intervention: Edaravone oral suspension administered via nasogastric tube (NGT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both oral and NGT administration
Number of subjects: 36
Study: 34450361

Group type: EXPERIMENTAL
Intervention: Active break intervention
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Postural shift intervention
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (placebo seat pad)
Number of subjects: 193
Study: 36388825

Group type: EXPERIMENTAL
Intervention: External diaphragmatic pacing (EDP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 51
Study: 32048274

Group type: EXPERIMENTAL
Intervention: Single dose of iv dexamethasone 24 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two consecutive doses of iv dexamethasone 24 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching iv placebo
Number of subjects: 0
Study: 35666927

Group type: EXPERIMENTAL
Intervention: Mobile phone disruptions
Number of subjects: 114

Group type: COMPARATOR
Intervention: Social disruptions
Number of subjects: 114

Group type: COMPARATOR
Intervention: Undisrupted play
Number of subjects: 114
Study: 33001159

Group type: EXPERIMENTAL
Intervention: Timolol eyedrops, 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo eyedrops (carboxymethyl cellulose, 0.5%)
Number of subjects: 50
Study: 33496201

Group type: COMPARATOR
Intervention: Intensive medical therapy optimization (6-week period)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ranolazine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ivabradine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Isosorbide mononitrate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 200

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 200
Study: 32613374

Group type: EXPERIMENTAL
Intervention: Supportive Health Education (SHE)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Telephone Interpersonal Counseling (TIPC)
Number of subjects: 350
Study: 34101208

Group type: EXPERIMENTAL
Intervention: PT + PBM
Number of subjects: 26

Group type: COMPARATOR
Intervention: PT + Sham
Number of subjects: 26